5α-还原酶抑制剂对低危前列腺癌主动监测患者疾病重分级的影响
回顾性分析371例经重复活检确认无Gleason升级的主动监测前列腺癌患者,其中70例(19%)在诊断后12个月内开始使用非那雄胺或多沙唑嗪。中位随访时间用药组53个月 vs 未用药组35个月(p<0.01),总体重分级率13% vs 14%(p=0.75),多变量Cox回归显示5α-还原酶抑制剂与重分级无显著关联(HR 0.80,95%CI 0.31-1.80,p=0.62)。
要点
- 用药组与未用药组总体重分级率无显著差异(13% vs 14%,p=0.75)。
- 多变量校正后5α-还原酶抑制剂与重分级无显著关联(HR 0.80,95%CI 0.31-1.80,p=0.62)。
- 根治性前列腺切除标本不良特征在用药组与未用药组间无差异(p=0.36)。
核心结论
- 在本主动监测队列中,5α-还原酶抑制剂的使用与随时间发生的分级重分类无显著差异相关。
研究设计与样本
- 回顾性综述纳入2002至2015年间635例主动监测患者,其中371例经重复活检确认无Gleason升级而纳入队列。
- 患者按诊断后1年内是否接受非那雄胺或多沙唑嗪分层,主要终点为后续活检中Gleason评分或主要Gleason模式任何增加的分级重分类,采用多变量Cox比例风险回归分析。
主要发现
- 诊断时371例符合纳入标准,其中70例(19%)在12个月内开始使用5α-还原酶抑制剂。
- 用药组与未用药组的中位主动监测时间分别为53个月 vs 35个月(p<0.01)。
- 用药组使用5α-还原酶抑制剂的中位时间为23个月(IQR 6-37)。
- 总体及极低/低危亚组中,5α-还原酶抑制剂使用与分级重分类在 actuarial 分析中无显著差异。
- 总体分级重分类发生率用药组13% vs 未用药组14%(p=0.75)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We determined the effect of 5α-reductase inhibitors on disease reclassification in men with prostate cancer optimally selected for active surveillance. MATERIALS AND METHODS: In this retrospective review we identified 635 patients on active surveillance between 2002 and 2015. Patients with favorable cancer features on repeat biopsy, defined as absent Gleason upgrading, were included in the cohort. Patients were stratified by those who did or did not receive finasteride or dutasteride within 1 year of diagnosis. The primary end point was grade reclassification, defined as any increase in Gleason score or predominant Gleason pattern on subsequent biopsy. This was assessed by multivariable Cox proportional hazards regression analysis. RESULTS: At diagnosis 371 patients met study inclusion criteria, of whom 70 (19%) were started on 5α-reductase inhibitors within 12 months. Median time on active surveillance was 53 vs 35 months in men on vs not on 5α-reductase inhibitors (p <0.01). Men on 5α-reductase inhibitors received them for a median of 23 months (IQR 6-37). On actuarial analysis there was no significant difference in grade reclassification for 5α-reductase inhibitor use in patients overall or in the very low/low risk subset. The overall percent of patients who experienced grade reclassification was similar at 13% vs 14% (p = 0.75). After adjusting for baseline clinicopathological features 5α-reductase inhibitors were not significantly associated with grade reclassification (HR 0.80, 95% CI 0.31-1.80, p = 0.62). Furthermore, no difference in adverse features on radical prostatectomy specimens was observed in treated patients (p = 0.36). CONCLUSIONS: Among our cohort of men on active surveillance 5α-reductase inhibitor use was not associated with a significant difference in grade reclassification with time.
引用
- Dai C, Ganesan V, Zabell J, et al. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features. J Urol. 2017. PMID: 28789947. doi:10.1016/j.juro.2017.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。